Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer

Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Clinical Cancer Research (Impact Factor: 8.72). 10/2009; 15(21):6639-48. DOI: 10.1158/1078-0432.CCR-09-0951
Source: PubMed


Inflammatory breast cancer (IBC) is a rare but aggressive type of advanced breast cancer. Epidermal growth factor receptor (EGFR) expression is an independent poor prognostic factor in IBC. The purpose of this study was to determine the effect on IBC tumorigenicity and metastasis of blocking the EGFR pathway.
IBC cell lines, which express high level of EGFR, were treated with EGFR small interfering RNA and with the EGFR tyrosine kinase inhibitor erlotinib. The role of EGFR in IBC cell proliferation, motility, invasiveness, and change of the expression levels of epithelial-mesenchymal transition markers was examined. The role of extracellular signal-regulated kinase (ERK)-1/2 in erlotinib activity was also studied. The activity of erlotinib in tumor growth and metastasis was examined in an orthotopic xenograft model of IBC.
Erlotinib inhibited proliferation and anchorage-independent growth of IBC cells, and this inhibition was ERK dependent. Erlotinib inhibited cell motility and invasiveness and reversed the mesenchymal phenotype of IBC cells to epithelial phenotype in three-dimensional culture. Erlotinib dramatically inhibited IBC tumor growth in a xenograft model. Interestingly, erlotinib inhibited spontaneous lung metastasis, even at a low dose that had no significant effect on primary tumor growth. These erlotinib-treated tumors were converted to epithelial phenotype from mesenchymal phenotype.
The EGFR pathway is involved in tumor growth and metastasis of IBC. Targeting EGFR through the ERK pathway may represent an effective therapeutic approach to suppress tumorigenicity and prevent metastasis in EGFR-expressing IBC.

Download full-text


Available from: Naoto T Ueno
  • Source
    • "E-mail: Received 14 April 2015; Revised 28 July 2015; Accepted 10 August 2015 preclinical models [17] [18] [19] [20] [21] [22] [23] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many malignant characteristics of cancer cells are regulated through pathways induced by the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Herein, we show that besides directly affecting the biology of cancer cells per se, EGFR also regulates the primary tumor microenvironment. Specifically, our findings demonstrate that both the expression and signaling activity of EGFR are required for the induction of a distinct intratumoral vasculature capable of sustaining tumor cell intravasation, a critical rate-limiting step in the metastatic cascade. An intravasation-sustaining mode of intratumoral angiogenic vessels depends on high levels of tumor cell EGFR and the interplay between EGFR-regulated production of interleukin 8 by tumor cells, interleukin-8–induced influx of tumor-infiltrating neutrophils delivering their unique matrix metalloproteinase-9, and neutrophil matrix metalloproteinase-9–dependent release of the vascular permeability and endothelial growth factor, VEGF. Our data indicate that through VEGF-mediated disruption of endothelial layer integrity and increase of intratumoral vasculature permeability, EGFR activity significantly facilitates active intravasation of cancer cells. Therefore, this study unraveled an important but overlooked function of EGFR in cancer, namely, its ability to create an intravasation-sustaining microenvironment within the developing primary tumor by orchestrating several interrelated processes required for the initial steps of cancer metastasis through vascular routes. Our findings also suggest that EGFR-targeted therapies might be more effective when implemented in cancer patients with early-staged primary tumors containing a VEGF-dependent angiogenic vasculature. Accordingly, early EGFR inhibition combined with various anti-VEGF approaches could synergistically suppress tumor cell intravasation through inhibiting the highly permeable angiogenic vasculature induced by EGFR-overexpressing aggressive cancer cells.
    Full-text · Article · Aug 2015 · Neoplasia (New York, N.Y.)
  • Source
    • "Therefore, it was suggested that Erlotinib functions through inhibition of epithelialmesenchymal transition (EMT) (Zhang D. et al, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study demonstrates crosstalk between Growth Hormone (GH) and Epidermal Growth Factor (EGF) in two different breast cancer cell lines. Long-term modification of cell viability and the ERK1/2 and AKT pathways was only detected in MDA-231 cells. By simultaneous treatment with GH and EGF, the interaction between GH and EGF in MCF-7 cells could be transiently abrogated by GH-pre-treatment. Co-treatment with GH and EGF diminished cell viability in MCF-7 and MDA-231 cells. Furthermore, a direct influence between GH and EGF signaling resulted in less ERK phosphorylation in MCF-7 cells, whereas in MDA-231 cells less AKT phosphorylation could be observed. EGFR-down regulation due to GH is a potential reason but keeps to be elucidated.
    Preview · Article · Jan 2015
  • Source
    • "In addition, to focus on the roots of resistance, we chose not to rely on cell proliferation assays. We tested the EGFR inhibitor erlotinib and the MEK inhibitor AZD6244; both targets, EGFR and MEK, are commonly active in TNBC and particularly in the SUM149 cell line [30]. We found that MA cells were more resistant to both of these inhibitors than the parental cell line was. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A major obstacle in developing effective therapies against solid tumors stems from an inability to adequately model the rare subpopulation of panresistant cancer cells that may often drive the disease. We describe a strategy for optimally modeling highly abnormal and highly adaptable human triple-negative breast cancer cells, and evaluating therapies for their ability to eradicate such cells. To overcome the shortcomings often associated with cell culture models, we incorporated several features in our model including a selection of highly adaptable cancer cells based on their ability to survive a metabolic challenge. We have previously shown that metabolically adaptable cancer cells efficiently metastasize to multiple organs in nude mice. Here we show that the cancer cells modeled in our system feature an embryo-like gene expression and amplification of the fat mass and obesity associated gene FTO. We also provide evidence of upregulation of ZEB1 and downregulation of GRHL2 indicating increased epithelial to mesenchymal transition in metabolically adaptable cancer cells. Our results obtained with a variety of anticancer agents support the validity of the model of realistic panresistance and suggest that it could be used for developing anticancer agents that would overcome panresistance.
    Full-text · Article · Oct 2014 · PLoS ONE
Show more